2025 Data Challenge

Scientific research has responded to the threat of antimicrobial resistance (AMR) with the development and regulatory approval of a number of new drugs over the past decade. However, the challenge of AMR is dynamic, evolving over time and space. While these new drugs benefit from their limited time on the market, little is known about how effective they may be geographically, or across the global landscape. Using knowledge gained from literature, our previous work, and surveillance data from databases such as Innoviva Specialty Therapeutics - Surveillance of global clinical isolates of Acinetobacter baumannii, Pfizer – ATLAS Antibiotics, and Venatorx – GEARS, we aim to develop a model for estimating the efficacy of novel antibiotics in regions where the drug is not yet available. Essentially, the model will rely on the data of previous isolates where cross-resistance and genetic information corresponding to resistance to newly approved compounds has been identified. Then, this information will be applied to a larger dataset to further validate the predictivity and pinpoint worrisome isolates and geographic areas interest. Subsequently, this tool could aid companies in identifying regions where their drug may perform well while also identifying hot spots where additional work to combat AMR is needed.

Previously, CAIRD has been involved or still has active, domestic surveillance studies for tebipenem, sulbactam/durolobactam, cefiderocol, and imipenem/relebactam. Additionally, we have a repository of more than 15,000 multidrug-resistant isolates from previous, like studies. This large pool of isolates and data to draw upon allows for a massive compare/contrast study to the Vivli data. Additionally, CAIRD is also expanding upon this work adding new hospital and isolates from around the world. So, the complementary dataset will significantly increase and provide a real-time dynamic that can be retested throughout the length of the project once parameters are set.